• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Advancement of cell-penetrating peptides in combating triple-negative breast cancer
Drug Discov Today. 2022 Sep 10:103353. doi: 10.1016/j.drudis.2022.103353. Online ahead of print.ABSTRACTExtensive research efforts have been made and are still ongoing in the search for an ideal anti-cancer therapy. Almost all chemotherapeutics require a carrier or vehicle, a drug delivery system that can transport the drug specifically to the targeted cancer cells, sparing normal cells. Cell-penetrating peptides (CPPs) provide an effective and efficient pathway for the intra-cellular transportation of various bioactive molecules in several biomedical therapies. They are now well-recognized as facilitators of intracellular...
Source: Drug Discovery Today - September 13, 2022 Category: Drugs & Pharmacology Authors: Mahak Fatima Mohammed A S Abourehab Geeta Aggarwal Gaurav K Jain Amirhossein Sahebkar Prashant Kesharwani Source Type: research

Development of siRNA Delivery System by Lipid Nanoparticles Modified with Functional Materials for Cancer Treatment
Biol Pharm Bull. 2022;45(8):972-977. doi: 10.1248/bpb.b22-00317.ABSTRACTNucleic acid drugs can control gene expression and function in a manner different from that of conventional compounds. On the other hand, nucleic acids can be easily degraded in the in vivo circumstances. In addition, nucleic acids cannot penetrate cell membranes. Therefore, a drug delivery system (DDS) is essential to protect nucleic acid molecules until they reach the target cell and to release them efficiently inside the cell. In order to apply nucleic acid drugs to new cancer therapeutic strategies, the author has been developing a DDS that enables...
Source: Biological and Pharmaceutical Bulletin - July 31, 2022 Category: Drugs & Pharmacology Authors: Yu Sakurai Source Type: research

Delivery of small interfering RNAs by nanovesicles for cancer therapy
Drug Metab Pharmacokinet. 2021 Oct 15;42:100425. doi: 10.1016/j.dmpk.2021.100425. Online ahead of print.ABSTRACTSmall interfering ribonucleic acids (siRNAs) are originally recognized as an intermediate of the RNA interference (RNAi) pathway. They can inhibit or silence various cellular pathways by knocking down specific messenger RNA molecules. In cancer cells, siRNAs can suppress the expression of several multidrug-resistant genes, leading to the increased deposition of chemotherapeutic drugs at the tumor site. siRNA therapy can be used to selectively increase apoptosis of cancer cells or activate an immune response to th...
Source: Drug Metabolism and Pharmacokinetics - December 26, 2021 Category: Drugs & Pharmacology Authors: Supusson Pengnam Samarwadee Plianwong Boon-Ek Yingyongnarongkul Prasopchai Patrojanasophon Praneet Opanasopit Source Type: research

RNA Drug Delivery Using Biogenic Nanovehicles for Cancer Therapy
RNA-based therapies have been promising method for treating all kinds of diseases, and four siRNA-based drugs and two mRNA-based drugs have been approved and are on the market now. However, none of them is applied for cancer treatment. This is not only because of the complexity of the tumor microenvironment, but also due to the intrinsic obstacles of RNAs. Until now, all kinds of strategies have been developed to improve the performance of RNAs for cancer therapy, especially the nanoparticle-based ones using biogenic materials. They are much more compatible with less toxicity compared to the ones using synthetic polymers, ...
Source: Frontiers in Pharmacology - December 24, 2021 Category: Drugs & Pharmacology Source Type: research

Delivery of siRNA Using Functionalized Gold Nanorods Enhances Anti-Osteosarcoma Efficacy
This study provides a new reference to improve the efficacy of OS clinically.
Source: Frontiers in Pharmacology - December 20, 2021 Category: Drugs & Pharmacology Source Type: research

Simultaneous nanocarrier-mediated delivery of siRNAs and chemotherapeutic agents in cancer therapy and diagnosis: Recent advances
Eur J Pharmacol. 2021 Dec 14:174639. doi: 10.1016/j.ejphar.2021.174639. Online ahead of print.ABSTRACTRecently, investigations have revealed that RNA interference (RNAi) has a remarkable potential to decrease cancer burden by downregulating genes. Among various RNAi molecules, small interfering RNA (siRNA) has been more attractive for this goal and is able to silence a target pathological path and promote the degradation of a certain mRNA, resulting in either gain or loss of function of proteins. Moreover, therapeutic siRNAs have exhibited low side effects compared to other therapeutic molecular candidates. Nevertheless, s...
Source: European Journal of Pharmacology - December 17, 2021 Category: Drugs & Pharmacology Authors: Negar Bidar Majid Darroudi Ailin Ebrahimzadeh Mohammadreza Safdari Miguel de la Guardia Behzad Baradaran Vahabodin Goodarzi Fatemeh Oroojalian Ahad Mokhtarzadeh Source Type: research

Pages: 1  2  3  4  5  6  7